GlassScriptPhysician profile
Holly Beth King
NPI 1720806326
$2,972.15
in general payments reported to CMS, 2019-2025
17 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $524.76 | 2025 | Caplyta |
| Corium, LLC | $464.81 | 2025 | Azstarys |
| Abbvie INC. | $409.85 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $288.02 | 2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $285.01 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $231.50 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $170.09 | 2025 | Auvelity |
| Alkermes, INC. | $163.11 | 2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $134.83 | 2025 | Jornay Pm |
| Lundbeck LLC | $84.81 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.74 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $36.88 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $35.31 | 2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $28.72 | 2025 | Relexxii |
| Tris Pharma INC | $17.53 | 2025 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $13.68 | 2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $13.50 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.